Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 26, 2020June 26, 2020

Way of Fine-tuning Vagus Nerve Stimulation, Potential PH Therapy, Seen

News

Anodal block, a technique based on electrical nerve stimulation, allows for the selective activation of fibers in the vagus nerve, a key nerve that runs through the neck and ... Read more

June 22, 2020June 22, 2020

Tiny RNA Molecule, MicroRNA-483, May Help Ease PAH, Early Study Finds

News, PAH News

Increasing the levels of a tiny RNA molecule known as microRNA-483 enhanced the function of endothelial cells and eased the symptoms of pulmonary arterial hypertension (PAH) in rat models of the disease, a ... Read more

June 8, 2020June 8, 2020

Levosimendan Seen to Ease Pressure on Heart in High-need PH Patient Group

News

Six weeks of treatment with levosimendan significantly lowered pressure on the heart and improved physical capacity among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), findings ... Read more

May 29, 2020May 29, 2020

Epigenetic Changes May Boost PAH Development, Study Reports

News, PAH News

Changes in the epigenetic profile — a collection of marks that turn genes on and off — of pulmonary arterial endothelial cells from people with pulmonary arterial hypertension (PAH) ... Read more

May 27, 2020June 16, 2020

Kalytera to Acquire R-107, Potential Liquid Nitric Oxide Treatment for PAH

News, PAH News

Kalytera Therapeutics intends to acquire Salzman Group, a company developing R-107 — a liquid form of nitric oxide — to possibly treat pulmonary arterial hypertension (PAH), lung disease associated with COVID-19, and other ... Read more

May 4, 2020May 4, 2020

PAH Trials Pausing Enrollment for COVID-19, United Therapeutic Says

News, PAH News, PH News

United Therapeutics has temporarily stopped enrolling patients in ongoing clinical trials of treprostinil-based therapies for pulmonary arterial hypertension (PAH) amid the COVID-19 pandemic, the company announced. Treprostinil is a man-made version of the ... Read more

April 27, 2020April 27, 2020

Benefits of Orenitram for PAH Patients Detailed in New Data

News, PAH News

United Therapeutics’ Orenitram (treprostinil) improves heart function and lowers risk status in people with pulmonary arterial hypertension (PAH) who had begun treatment with another approved therapy, new data from a Phase ... Read more

April 17, 2020April 17, 2020

Exosomes from Stem Cells May Slow Vascular Remodeling in PAH

News, PH News

Small vesicles, called exosomes, released by mesenchymal stem cells helped to ease vascular remodeling in a rat model of pulmonary hypertension (PH), a study reports. The study “Mesenchymal stromal ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

March 6, 2020March 6, 2020

Mutations in BMPR2 Gene More Common in Men with PAH, Study Reports

News, PAH News

Men with pulmonary arterial hypertension (PAH) are more likely to carry mutations in the BMPR2 gene, a known genetic risk factor for PAH, a study from China found. Male ... Read more

Pin It on Pinterest